Related Experiment Video
Updated: Feb 9, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels
G Poelzl1, S K Ghadge1, M Messner1
1Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.
Insights
Fibroblast growth factor 23 (FGF23) levels predict chronic heart failure progression. Soluble Klotho (sKlotho) in serum does not, but Klotho is upregulated in diseased hearts, suggesting local effects.
Area of Science:
- Cardiology
- Endocrinology
- Gerontology
Background:
- Klotho is an antiaging protein with known cardioprotective effects.
- Trans-membrane Klotho functions as a fibroblast growth factor 23 (FGF23) co-receptor in the kidney.
- Soluble Klotho (sKlotho) offers cardioprotection against systolic dysfunction, independent of FGF23.
Purpose of the Study:
- To investigate the association between FGF23, sKlotho, and chronic heart failure (CHF) progression.
- To analyze Klotho expression in human heart tissue from patients with cardiomyopathy (CMP).
Main Methods:
- Serum levels of sKlotho and FGF23 were measured in 287 CMP patients.
- Klotho mRNA and protein expression were analyzed in human CMP and control heart tissues.
- Immunoblotting was used to confirm sKlotho upregulation and protease expression.
Main Results:
- Patients in the lowest FGF23 tertile had a 4.1-fold higher likelihood of remaining free from adverse outcomes.
- No correlation was found between serum sKlotho levels and the combined endpoint.
- Klotho mRNA was upregulated in human CMP hearts, with increased sKlotho and associated proteases.
Conclusions:
- Serum FGF23, but not sKlotho, is associated with chronic heart failure progression.
- Klotho is upregulated in diseased hearts, indicating potential local paracrine functions.
- These findings suggest distinct roles for FGF23 and local Klotho in heart failure pathophysiology.
Abstract:
Klotho is an antiaging protein which exerts known cardioprotection. In kidney, trans-membrane Klotho acts as essential co-receptor of fibroblast growth factor 23 (FGF23). In the heart, soluble Klotho (sKlotho) protects from systolic dysfunction independently of FGF23. Here, we analyzed the association of FGF23 and sKlotho upon progression of chronic heart failure (CHF) and analyzed Klotho expression in human hearts. Serum levels of sKlotho and FGF23 were measured in 287 patients with cardiomyopathy (CMP). Tissue samples from CMP (n = 10) and healthy control hearts (n = 10) were analyzed for Klotho mRNA and protein expression. Individuals in the first FGF23 tertile were 4.1 times more likely of freedom from death, heart transplantation or assist device implantation compared to third tertile. No relationship was found between sKlotho and the combined endpoint. Instead, Klotho mRNA encoding the full-length form was upregulated in human CMP hearts. Immunoblotting confirmed upregulation of sKlotho associated with increased expression of proteases involved in cleavage of Klotho suggesting rather local effects of Klotho in the heart. Therefore, we conclude that in contrast to FGF23, serum sKlotho is not associated with disease severity or progression in CHF. Instead, Klotho is expressed and upregulated in diseased hearts, suggesting local paracrine effects.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:
Hypothesis Test for Test of Independence
H0: The two variables (factors)...
Law of Independent Assortment

